Redirecting T lymphocyte specificity using T cell receptor genes.
Redirecting T cells by transferring T cell receptor (TCR) genes from tumor-associated antigen (TAA)-reactive T cell clones into human peripheral blood lymphocytes (PBL) has therapeutic potential for the treatment of diseases, including cancer. T cell specificity can be altered using retroviruses encoding TCRalpha and TCRbeta chain genes, or chimeric immunoglobulin (cIg) genes containing signaling domains of CD3 zeta or Fc epsilon RI-gamma. This review evaluates recent studies using TCRs and cIgs to redirect T cell specificity and discusses some of the technical and biological hurdles that need to be addressed before these approaches can be successfully used to treat patients.
Department of Surgery, University of Chicago, Chicago, Illinois 60637, USA.
Barbara L F
BL
Kaplan
David C
DC
Yu
Timothy M
TM
Clay
Michael I
MI
Nishimura
D006801:Humans; D019169:Jurkat Cells; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*; D013601:T-Lymphocytes / Q000276:immunology*; D014162:Transfection
D011948:Receptors, Antigen, T-Cell